Keros Therapeutics posts Q1 net loss as license revenue drops

Keros Therapeutics

14/05/2026 13:08

Overview

US biopharma firm's Q1 net loss follows prior-year profit due to lower license revenue

Research and development expenses fell after elritercept costs shifted to Takeda and 2025 restructuring

Company expects cash reserves to fund operations into first half of 2028

Outlook

Company expects cash and cash equivalents to fund operations into the first half of 2028

Result Drivers

LICENSE REVENUE DROP - Absence of prior-year license revenue from Takeda agreement drove decline in Q1 results

R&D COST SHIFT - Research and development expenses fell as elritercept-related costs moved to Takeda and after 2025 restructuring

LOWER ADMIN COSTS - General and administrative expenses decreased due to lower compensation costs after 2025 restructuring

Company press release: ID:nGNX8PMjYL

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$23.71 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Keros Therapeutics Inc is $20.00, about 66.8% above its May 13 closing price of $11.99

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)